EOC202

BIOLOGICAL2 trials

Sponsors

Taizhou EOC Pharma Co., Ltd.

Conditions

Solid Tumor, Adult

Phase 1

Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer

CompletedNCT03600090

Taizhou EOC Pharma Co., Ltd.Solid Tumor, Adult

Start: 2018-10-16End: 2021-12-25Updated: 2022-03-31

Phase 2

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

Taizhou EOC Pharma Co., Ltd.Solid Tumor, Adult

Start: 2022-04-30End: 2025-05-31Target: 50Updated: 2022-04-12